

09/762152

Rec'd PCT/PTO 01 FEB 2001

RR-473PCT/US

**METHOD AND APPARATUS FOR TREATMENT OF
RESPIRATORY INFECTIONS BY NITRIC OXIDE INHALATION**

Chris C. MILLER

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is
being deposited with the U.S. Postal Service
as EXPRESS MAIL, Customer Receipt No.
EL1253394574US, in an envelope addressed
to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on February 2, 2001
Date


Applicant's Attorney

6pts

09/762152
10 FEB 2001

WO 00/30659

PCT/CA99/01123

METHOD AND APPARATUS FOR TREATMENT OF RESPIRATORY INFECTIONS
BY NITRIC OXIDE INHALATION

FIELD OF THE INVENTION

5

10

The present invention relates to a method for suppressing pathogenic cells, as well as a method for the treatment of an animal, including a human, having pathogenic cells within its respiratory tract. These methods preferably comprise the exposure of the pathogenic cells to an effective amount of a source of nitric oxide, the nitric oxide source comprising nitric oxide or a compound or substance capable of producing nitric oxide and wherein the nitric oxide may have either an inhibitory or a cidal effect on such pathogenic cells.

15

Further, the present invention relates to the use of nitric oxide for suppressing pathogenic cells, the therapeutic use of nitric oxide for the treatment of an animal having pathogenic cells in its respiratory tract and a pharmaceutical composition for such treatment.

20

25

As well, in a preferred embodiment, the present invention relates to the use of nitric oxide in a gaseous form (NO) in the treatment of fungal, parasitic and bacterial infections, particularly pulmonary infection by mycobacterium tuberculosis. The invention also relates to an improved apparatus or device for the delivery, particularly pulsed-dose delivery, of an effective amount of nitric oxide for the treatment of microbial based diseases which are susceptible to nitric oxide gas. The device preferably provides nitric oxide replacement therapy at a desired dose for infected respiratory tract infections, or provides nitric oxide as a sterilizing agent for medical and other equipment, instruments and devices requiring sterilization.

BACKGROUND OF THE INVENTION

30

In healthy humans, endogenously synthesized nitric oxide (NO) is thought to exert an important mycobacteriocidal or inhibitory action in addition to a

vasodilatory action. There have been a number of ongoing, controlled studies to ascertain the benefits, safety and efficacy of inhaled nitric oxide as a pulmonary vasodilator. Inhaled nitric oxide has been successfully utilized in the treatment of various pulmonary diseases such as persistent pulmonary hypertension in newborns and adult respiratory distress syndrome. There has been no attempt, however, to reproduce the microbacteriocidal or inhibitory action of NO with exogenous NO.

Further background information relating to the present invention may be found in the following references:

1. Lowenstein, C.J., J.L. Dinerman, and S.H. Snyder. 1994. Nitric oxide: a physiologic messenger" *Ann. Intern. Med.* 120:227-237.
2. The neonatal inhaled nitric oxide study group. 1997. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *N. Engl. J. Med.* 336:597-604.
3. Roberts, J.D. Jr., J.R Fineman, F.C. Morin III, et al. for the inhaled nitric oxide study group. 1997. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. *N. Engl. J. Med.* 336:605-610.
4. Rossaint, R., K.J. Falke, F. Lopez, K. Slama, U. Pison, and W.M. Zapol. 1993. Inhaled nitric oxide for the adult respiratory distress syndrome. *N. Engl. J. Med.* 328:399-405.
5. Rook, G.A.W. 1997. Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? *Thorax*. 52 (Suppl 3):S41-S46.
6. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. *Cell. Immunol.* 132:150-157.
7. Chan, J., R. Xing, R.S. Magliozzo, and B.R. Bloom. 1992. Killing of virulent *Mycobacterium tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. *J. Exp. Med.* 175:1111-1122.

8. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B.R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with *Mycobacterium tuberculosis*. *Infect. Immun.* 63:736-740.
9. Nozaki, Y., Y. Hasegawa, S. Ichiyama, I. Nakashima, and K. Shimokata. 1997. Mechanism of nitric oxide - dependent killing of *Mycobacterium bovis* BCG in human alveolar macrophages. *Infect. Immun.* 65:3644-3 647.
10. Canetti, G. 1965. Present aspects of bacterial resistance in tuberculosis. *Am. Rev. Respir. Dis.* 92:687-703.
11. Hendrickson, D.A., and M.M. Krenz. 1991. Regents and stains, P. 1289-1314. In Balows, A, W.J. Hausler Jr., K.L. Herrmann, H.D. Isenberg, and 1-li. Shadomy (eds.), *Manual of Clinical Microbiology*, 5th ed., 1991. American Society for Microbiology, Washington, D.C.
12. Szabo, C. 1996. The pathophysiological role of peroxynitrite in shock, inflammation and ischemia - reperfusion injury. *Shock.* 6:79-88.
13. Stavert, D.M., and B.E. Lehnert. 1990. Nitrogen oxide and nitrogen dioxide as inducers of acute pulmonary injury when inhaled at relatively high concentrations for brief periods. *Inhal. Toxicol.* 2:53-67.
14. Hugod, C. 1979. Effect of exposure to 43 PPM nitric oxide and 3.6 PPM nitrogen dioxide on rabbit lung. *mt. Arch. Occup. Environ. Health.* 42:159-167
15. Frostell, C., M.D. Fratacci, J.C. Wain, R. Jones and W.M. Zapol. 1991. Inhaled nitric oxide, a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. *Circulation.* 83:2038-2047.
16. Bult, H., G.R.Y. De Meyer, F.H. Jordaens, and A.G. Herman. 1991. Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy. *J. Cardiovasc. Pharmacol.* 17:S79-S82.
17. Buga, G.M., J.M. Griscavage, N.E. Rogers, and L.J. Ignarro. 1993. Negative feedback regulation of endothelial cell function by nitric oxide. *Circ. Res.* 73:808-8 12
18. Assreuy, J., F.Q. Cunha, F.Y. Liew, and S. Moncada. 1993. Feedback inhibition of nitric oxide synthase activity by nitric oxide. *Br. J. Pharmacol.* 108:833-837.

19. O'Brien, L., J. Carmichael, D.B. Lowrie and P.W. Andrew. 1994. Strains of *Mycobacterium tuberculosis* differ in susceptibility to reactive nitrogen intermediates in vitro. *Infect. Immun.* 62:5187-5190.
20. Long, R., B. Maycher, A. Dhar, J. Manfreda, E. Hershfield, and N.R. Anthonisen. 1998. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. *Chest.* 113:933-943.
21. Bass, H., J.A.M. Henderson, T. Heckscher, A. Oriol, and N.R. Anthonisen. 1968. Regional structure and function in bronchiectasis. *Am. Rev. Respir. Dis.* 97:598-609.

SUMMARY OF THE INVENTION

In a first aspect of the invention, the invention relates to a method for suppressing pathogenic cells, and a method for treating an animal having pathogenic cells in its respiratory tract, utilizing a source of nitric oxide. More particularly, in the first aspect of this invention, the invention relates to a method for suppressing pathogenic cells comprising the step of exposing the pathogenic cells to an effective amount of a nitric oxide source. Further, the invention relates to a method for treating an animal having pathogenic cells in the respiratory tract of the animal comprising the step of delivering by the inhalation route to the respiratory tract of the animal an effective amount of a nitric oxide source.

In a second aspect of the invention, the invention relates to a use and a therapeutic use of a source of nitric oxide for suppressing or treating pathogenic cells. More particularly, in the second aspect of the invention, the invention relates to the use of an effective amount of a nitric oxide source for suppressing pathogenic cells exposed thereto. Further, the invention relates to the therapeutic use of an effective amount of a nitric oxide source for the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal. Preferably, as discussed further below, the present invention relates to the novel use of inhaled nitric oxide gas as an agent for killing bacterial cells, parasites and fungi in the treatment of respiratory infections.

In a third aspect of the invention, the invention relates to a pharmaceutical composition for use in treating an animal having pathogenic cells in its respiratory tract, which composition comprises a nitric oxide source. More particularly, in the third aspect of the invention, the invention relates to a pharmaceutical composition for use in the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal, the pharmaceutical composition comprising an effective amount of a nitric oxide source.

Finally, in a fourth aspect of the invention, the invention relates to an apparatus or device for supplying, delivering or otherwise providing a nitric oxide source. Preferably, the apparatus or device provides the nitric oxide source for the particular applications, methods and uses described herein. However, the apparatus or device may also be used for any application, method or use requiring the supply, delivery or provision of a nitric oxide source.

In all aspects of the invention, the nitric oxide source is preferably nitric oxide *per se*, and more particularly, nitric oxide gas. However, alternately, the nitric oxide source may be any nitric oxide producing compound, composition or substance. In other words, the nitric oxide source may be any compound, composition or substance capable of producing or providing nitric oxide, and particularly, nitric oxide gas. For instance, the compound, composition or substance may undergo a thermal, chemical, ultrasonic, electrochemical or other reaction, or a combination of such reactions, to produce or provide nitric oxide to which the pathogenic cells are exposed. As well, the compound, composition or substance may be metabolized within the animal being treated to produce or provide nitric oxide within the respiratory tract of the animal.

Further, in all aspects of the invention, the invention is for use in suppressing or treating any pathogenic cells. For instance, the pathogenic cells may be tumor or cancer cells. However, the pathogenic cells are preferably pathogenic microorganisms, including but not limited to pathogenic bacteria, pathogenic

parasites and pathogenic fungi. More preferably, the pathogenic microorganisms are pathogenic mycobacteria. In the preferred embodiment, the pathogenic mycobacteria is *M. tuberculosis*.

5 Referring to the use of the nitric oxide source and method for suppressing pathogenic cells using the nitric oxide source, as indicated, the nitric oxide source is preferably nitric oxide *per se*. However, the nitric oxide source may be a compound, composition or substance producing nitric oxide. In either event, the pathogenic cells are suppressed by the nitric oxide. Suppression of the pathogenic
10 cells by nitric oxide may result in either or both of an inhibitory effect on the cells and a cidal effect on the cells. However, preferably, the nitric oxide has a cidal effect on the pathogenic cells exposed thereto. Thus, it has been found that these aspects of the invention have particular application for the sterilization of medical and other equipment, instruments and devices requiring sterilization.

15 As well, the pathogenic cells may be exposed to the nitric oxide and the exposing step of the method may be performed in any manner and by any mechanism, device or process for exposing the pathogenic cells to the nitric oxide source, and thus nitric oxide, either directly or indirectly. However, in the preferred
20 embodiment, the pathogenic cells are directly exposed to the nitric oxide. As a result, where desired, the effect of the nitric oxide may be localized to those pathogenic cells which are directly exposed thereto.

25 Similarly, the therapeutic use, method for treating and pharmaceutical composition for treatment all deliver the nitric oxide source to the pathogenic cells in the respiratory tract of the animal. The therapeutic use, method and composition may be used or applied for the treatment of any animal, preferably a mammal, including a human. Further, as indicated, the nitric oxide source in these instances is also preferably nitric oxide *per se*, however, the nitric oxide source may be a
30 compound, composition or substance producing nitric oxide within the respiratory tract. In either event, the nitric oxide similarly suppresses the pathogenic cells in the respiratory tract of the animal. This suppression of the pathogenic cells may result in

either or both of an inhibitory effect on the cells and a cidal effect on the cells. However, preferably, the nitric oxide has a cidal effect on the pathogenic cells in the respiratory tract exposed thereto.

5 As well, the pathogenic cells in the respiratory tract of the animal may be treated by nitric oxide and the delivering step of the therapeutic method may be performed in any manner and by any mechanism, device or process for delivering the nitric oxide source, and thus nitric oxide, either directly or indirectly to the respiratory tract of the animal. In the preferred embodiments of these aspects of the
10 invention, the nitric oxide source is delivered directly by the inhalation route to the respiratory tract of the animal, preferably by either the spontaneous breathing of the animal or by ventilated or assisted breathing.

Further, in the preferred embodiments of these aspects of the
15 invention, the pathogenic cells in the respiratory tract of the animal are treated by, and the delivering step of the therapeutic method is comprised of, exposing the pathogenic cells to the nitric oxide source, and thus nitric oxide, either directly or indirectly. More preferably, the pathogenic cells are directly exposed to the nitric oxide. As a result, where desired, the effect of the nitric oxide may be localized to
20 those pathogenic cells which are directly exposed thereto within the respiratory tract of the animal.

In addition, in all aspects of the invention, an effective amount of the nitric oxide source is defined by the amount of the nitric oxide source required to
25 produce the desired effect of the nitric oxide, either inhibitory or cidal, on the pathogenic cells. Thus, the effective amount of the nitric source will be dependent upon a number of factors including whether the nitric oxide source is nitric oxide *per se* or a nitric oxide producing compound, the desired effect of the nitric oxide on the pathogenic cells and the manner in which the pathogenic cells are exposed to or
30 contacted with the nitric oxide. In the preferred embodiments of the various aspects of the invention, the effective amount of the nitric oxide source is the amount of nitric oxide required to have a cidal effect on the pathogenic cells exposed directly

thereto. Thus, the effective amount for any particular pathogenic cells will depend upon the nature of the pathogenic cells and can be determined by standard clinical techniques. Further, the effective amount will also be dependent upon the concentration of the nitric oxide to which the pathogenic cells are exposed and the
5 time period or duration of the exposure.

Preferably, the pathogenic cells are exposed to a gas or a gas is delivered to the respiratory tract of the animal being treated, wherein the gas is comprised of the nitric oxide source. More preferably, the pathogenic cells are
10 exposed to a gas comprised of nitric oxide. For instance, the gas may be comprised of oxygen and nitric oxide for delivery by the inhalation route to the respiratory tract of the animal being treated.

Although in the preferred embodiments of the various aspects of the
15 invention, any effective amount of nitric oxide may be used, the concentration of the nitric oxide in the gas is preferably at least about 25 parts per million. Further, the concentration of the nitric oxide in the gas is preferably less than about 100 parts per million. Most preferably, the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.

Although the pathogenic cells may be exposed to the gas for any time
20 period or duration necessary to achieve the desired effect, the pathogenic cells are preferably exposed to the gas, or the gas is delivered to the respiratory tract of the animal, for a time period of at least about 3 hours. In the preferred embodiments of
25 the various aspects of the invention, the pathogenic cells are exposed to the gas, or the gas is delivered to the respiratory tract of the animal, for a time period of between about 3 and 48 hours.

Finally, in the fourth embodiment of the invention, the apparatus or
30 device is preferably comprised of a portable battery-operated, self-contained medical device that generates its own nitric oxide source, preferably nitric oxide gas, as a primary supply of nitric oxide. Further, the device may also include a conventional

compressed gas supply of the nitric oxide source, preferably nitric oxide gas, as a secondary back-up system or secondary supply of nitric oxide.

Further, the device preferably operates to deliver nitric oxide in the gaseous phase to spontaneously breathing or to ventilated individual patients having microbial infections, by way of a specially designed nasal-cannula or a mask having a modified Fruman valve. In the preferred embodiment, nitric oxide gas is produced in cartridges through thermal-chemical, ultrasonic and/or electrochemical reaction and is released upon user inspiratory demand in pulsed-dose or continuous flow.

BRIEF DESCRIPTION OF THE DRAWINGS

The nature and scope of the invention will be elaborated in the detailed description which follows, in connection with the enclosed drawing figures, in which:

Figure 1 illustrates an airtight chamber for exposure of mycobacteria to varying concentrations of nitric oxide (NO) in tests of in vitro measurements of the cidal effects of exogenous NO;

Figure 2 is a graphical representation of experimental data showing the relationship of percent kill of microbes to exposure time for fixed doses of NO;

Figure 3a shows the external features of a pulse-dose delivery device for nitric oxide according to the present invention;

Figure 3b illustrates schematically the internal working components of the device of Figure 3a;

Figure 4 is a schematic illustration of the specialized valve used to control the delivery of nitric oxide in a preset dosage through the disposable nasal cannula of a device according to the present invention; and

Figure 5 is a schematic drawing of the mask-valve arrangement of a pulsed-dose nitric oxide delivery device according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Studies of the Applicant on the exposure of extra cellular M. tuberculosis to low concentrations of NO for short periods have led to the conclusion that exogenous NO exerts a powerful dose-dependent and time-dependent mycobacteriocidal action. Further, it may be inferred that the large population of extracellular bacilli in patients with cavitary pulmonary tuberculosis are also vulnerable to exogenous (inhaled) NO.

Measurements of Cidal Activity of Exogenous NO

Referring to Figure 1, to re-create a normal incubation environment that allowed for the exposure of mycobacteria to varying concentrations of NO, an airtight "exposure chamber" (20) was built that could be seated in a heated biological safety cabinet (22). This chamber (20) measured 31 x 31 x 21 cm and is made of plexiglass. It has a lid (24) which can be firmly sealed, a single entry port (26) and a single exit port (28) through which continuous, low-flow, 5-10% CO₂ in air can pass, and a thermometer (30). A "Y" connector (32) in the inflow tubing allows delivery of NO, at predetermined concentrations, to the exposure chamber (20). Between the "Y" connector (32) and the exposure chamber (20) is a baffle box (34) which mixes the gases. Finally between the baffle box (34) and the exposure chamber (20) is placed an in-line NO analyzer (36), preferably a Pulmonox® Sensor manufactured by Pulmonox Medical Corporation, Tofield, Alberta, Canada. This analyzer (36) continuously measures NO concentration in the gas mixture entering the exposure chamber (20).

The day before conducting the experiments, a precise quantity of actively growing virulent *M. tuberculosis* was plated on solid media (38) (Middlebrook 7H-10 with OADC enrichment) after careful dilution using McFarland nephelometry (1 in 10 dilution, diluted further to an estimated 10^3 bacteria/ml and using a 0.1 ml inoculate of this suspension) (see Reference No. 11 above under the Background of the Invention). Control and test plates were prepared for each experiment. Control plates were placed in a CO₂ incubator (Forma Scientific, Marietta, Ohio) and incubated in standard fashion at 37 °C in 5-10% CO₂ in air.

Test plates were placed in the exposure chamber (20) for a pre-determined period of time after which they were removed and placed in the incubator along with the control plates. The temperature of the exposure chamber (20) was maintained at 32-34 °C. Colony counts were measured on control and test plates at 2, 3 and 6 weeks from the day of plating. Reported counts are those measured at three weeks expressed as a percentage of control.

Experiments were of two varieties: (1) those that involved exposure of the drug susceptible laboratory strain H37RV to fixed concentrations of NO, i.e. 0 (sham), 25, 50, 70 and 90 PPM for periods of 3, 6, 12, and 24 hours; and (2) those that involved exposure of a multidrug-resistant (isoniazid and rifampin) wild strain of *M. tuberculosis* to fixed concentrations of NO, i.e. 70 and 90 PPM for periods of 3, 6, 12 and 24 hours. One experiment at 90 PPM NO, that used both strains of *M. tuberculosis*, was extended to allow for a total exposure time of 48 hours. The NO analyzer (36) was calibrated at least every third experiment with oxygen (0 PPM of NO) and NO at 83 PPM.

Statistical Analysis

For each NO exposure time and NO concentration studied at least two, and in most cases three or four, separate experiments were performed with 3-6 exposure plates (38) per set. Colony counts performed on each exposure plate (38)

were expressed as a percentage of the mean colony count of the matched non-exposed control plates. The values from all experiments at each NO concentration and exposure time were then averaged. These data were analyzed using two-way analysis of variance using the F statistic to test for independent effects of NO exposure time and NO concentration and of any interaction between them on the colony counts.

Experimental Results

A diagram of the incubation environment is shown in Figure 1. This environment exactly simulated the usual incubation environment of *M. tuberculosis* in the laboratory, with the following exceptions: (1) the temperature of our exposure chamber (20) was maintained at 32-34°C rather than the usual 37°C to avoid desiccation of the nutrient media upon which the bacteria were plated; and (2) the test plates were openly exposed. That a stable and comparable incubation environment was reproduced was verified in four sham experiments using the H37RV laboratory strain of *M. tuberculosis*. Colony counts on plates (38) exposed to 5-10% CO₂ in air (0 PPM NO) at 32-34°C in the exposure chamber (20) were not significantly different from those on control plates placed in the laboratory CO₂ incubator at 37°C, as shown in Table 1, below:

TABLE 1
COLONY COUNTS AFTER EXPOSURE OF THE LABORATORY STRAIN (H37RV) OF
M. TUBERCULOSIS TO VARYING CONCENTRATIONS OF NITRIC OXIDE
FOR PERIODS OF 3, 6, 12 AND 24 HOURS

Colony Counts (Mean \pm SE) (expressed as percentage of control)				
NO (PPM)	Exposure Time (Hours)			
	3	6	12	24
0	107 \pm 5(6)*	100 \pm 5(6)	97 \pm 9(6)	105 \pm 5(18)
25	09 \pm 6(12)	109 \pm 4(12)	102 \pm 3(12)	66 \pm 4(18)
50	97 \pm 5 (12)	96 \pm 2 (12)	69 \pm 3 (12)	41 \pm 5 (18)

70	80 ± 10(7)	63 ± 12(7)	58 ± 12(11)	21 ± 6(11)
90	101 ± 15(11)	67 ± 7(11)	64 ± 7 (14)	15 ± 3(15)
* Numbers in brackets refer to the number of plates prepared for each NO concentration at each time interval.				

Seventeen experiments of the first variety, where plates (38) inoculated with a 0.1 ml suspension of 10^3 bacteria/ml of the H37RV strain of *M. tuberculosis* were exposed to a fixed concentration (either 0, 25, 50, 70 or 90 PPM) of NO for increasing periods of time (3, 6, 12 and 24 hours) were performed. The results have been pooled and are outlined in Table 1. There were both dose and time dependent

5 cidal effects of NO that were very significant by two-way ANOVA (F ratio 13.4, $P < .001$; F ratio 98.1, $P < 0.0001$ respectively) and there was also a statistically significant interactive effect on microbial killing efficacy (F ratio 2.03, $P < .048$). Although there was some variability in the percentage killed from experiment to experiment, increasing the standard error of the pooled data, the dose and time effect were highly reproducible. Only one control and one test (12 hour) plate at 90 PPM were contaminated. That the effect of NO was cidal and not inhibitory was confirmed by the absence of new colony formation beyond three weeks.

As described in Figure 2, the response to a fixed dose of NO was relatively linear with the slope of the line relating exposure time to percent kill increasing proportionally with the dose. Dose-related microbial killing did not appear to increase above 70 PPM NO, since colony counts at 70 and 90 PPM were

20 indistinguishable. At 24 hours of NO exposure at both the 70 and 90 PPM NO levels, more than one third of the exposed plates were sterile. One experiment at 90 PPM NO was extended to allow for a total exposure time of 48 hours; all of these plates were sterile (see Figure 2 and Table 2 below)

TABLE 2
COLONY COUNTS AFTER EXPOSURE OF A MULTIDRUG-RESISTANT WILD STRAIN OF
M. TUBERCULOSIS TO NITRIC OXIDE FOR PERIODS OF 3, 6, 12, 24 AND 48 HOURS

Colony Counts (Mean ± SE)
(expressed as percentage of control)

NO (PPM)	Exposure Time (Hours)				
	3	6	12	24	48
70	113 ± 2(4)	75 ± 4(4)	85 ± 10(4)	66 ± 4(4)	
			50 ± 25(4)	10 ± 5(4)	
90	97 ± 11(2)	91 ± 11(2)	71 ± 8(2)	36 ± 10(2)	
			59 ± 4(4)	32 ± 3(4)	0 ± 0(4)
			79 ± 5(4) #	20 ± 3(4) #	0 ± 0(4) #
* Each series represents an individual experiment; numbers in brackets refer to the number of plates prepared for each experiment at each time interval.					
# These results refer to the H37RV laboratory strain.					

Four experiments of the second variety, where plates inoculated with a 0.1 ml suspension of 10^3 bacteria/ml of a multidrug-resistant wild strain of *M. tuberculosis*, were exposed to a fixed concentration (either 70 or 90 PPM) of NO for increasing periods of time (3, 6, 12 and 24 hours) were performed, two at each of 70 and 90 PPM NO. Again there was a significant dose and time dependent cidal effect (see Table 2 above). Although the percent kill at 24 hours was less than that observed with the H37RV strain, when an inoculum of this strain was exposed to 90 PPM NO for a period of 48 hours there was also 100% kill.

Conclusion

Using an in vitro model in which the nitric oxide concentration of the incubation environment was varied, we have demonstrated that exogenous NO delivered at concentrations of less than 100 PPM exerts a powerful dose and time dependent mycobacteriocidal action. When an inoculate of *M. tuberculosis* that yielded countable colonies (0.1 ml of a suspension of 10^3 bacteria/ml) was plated on nutrient rich media and exposed to exogenous NO at 25, 50, 70 and 90 PPM for 24 hours there was approximately 30, 60, 80 and 85% kill, respectively. Similarly when plates of the same inocula were exposed to a fixed concentration of exogenous NO, for example 70 PPM, for increasing durations of time, the percentage of kill was

directly proportional to exposure time; approximately 20, 35, 40 and 80% kill at 3, 6, 12 and 24 hours, respectively.

Of added interest, the dose and time dependent mycobacteriocidal effect of NO was similar for both the H37RV laboratory strain and a multidrug-resistant (isoniazid and rifampin) wild strain of *M. tuberculosis*, (after 24 and 48 hours exposure to 90 PPM NO, there was 85 and 100% kill and 66 and 100% kill of the two strains, respectively) expanding the potential therapeutic role of exogenous NO and suggesting that the mechanism of action of NO is independent of the pharmacologic action of these cidal drugs.

The dominant mechanism(s) whereby intracellular NO, known to be produced in response to stimulation of the calcium-independent inducible nitric oxide synthase, results in intracellular killing of mycobacteria is still unknown (see Reference No. 5 above under the Background of the Invention). Multiple molecular targets exist, including intracellular targets of peroxynitrite, the product of the reaction between NO and superoxide (see Reference No. 12 above under the Background of the Invention). Whatever the mechanism(s), there is evidence that NO may be active not just in murine but also in human alveolar macrophages (see References No. 6 - 9 above under the Background of the Invention), and furthermore that this activity may be critical to the mycobacteriocidal action of activated macrophages. Whether macrophase inducible NOS produces NO that has extracellular activity is not known but it is reasonable to expect that a measure of positive (mycobacteriocidal) and negative (tissue necrosis) activity might follow the death of the macrophase itself.

The relative ease with which NO may be delivered exogenously, and its theoretical ability to rapidly destroy the extracellular population of bacilli in the patient with sputum smear positive pulmonary tuberculosis, especially drug-resistant disease, have great clinical appeal.

Primary Unit of the NO Post-Delivery Device

Referring to Figures 3a and 3b, the main unit (40) provides a small enclosure designed to hang on a belt. An A/C inlet (42) provides an electrical port to provide power to an internal rechargeable battery which powers the unit (40) if required. The user interface provides a multi-character display screen (44) for easy input and readability. A front overlay (46) with tactile electronic switches allows easy input from user to respond to software driven menu commands. LED and audible alarms (48) provide notification to user of battery life and usage. A Leur-type lock connector (50) or delivery outlet establishes communication with the delivery line to either the nasal cannula device (52) shown in Figure 4 or the inlet conduit on the modified Fruman valve (54) shown in Figure 5.

More particularly, referring to Figure 3b, the main unit (40) houses several main components. A first component or subassembly is comprised of an electronic/control portion of the device. It includes a microprocessor driven proportional valve or valve system (56), an alarm system, an electronic surveillance system and data input/output display system and electronic/software watch dog unit (44).

A second component or subassembly includes one or more disposable nitric oxide substrate cartridges (58) and an interface mechanism. A substrate converter system or segment (60) processes the primary compounds and converts it into pure nitric oxide gas. The gas then flows into an accumulator stable (62) and is regulated by the proportional valve assembly (56) into a NO outlet nipple (64).

A third component or subassembly is comprised of a secondary or backup nitric oxide system (66). It consists of mini-cylinders of high nitric oxide concentration under low-pressure. This system (66) is activated if and when the primary nitric oxide source (58) is found faulty, depleted or not available.

Nasal Cannula Adjunct

Referring to Figure 4, there is shown a detailed drawing of a preferred embodiment of a valve (68) used to control the delivery of nitric oxide in a preset dosage through a disposable nasal cannula device (52) as shown. The valve (68) is controlled by the natural action of spontaneous respiration by the patient and the dosage is preset by the physical configuration of the device (52).

The device (52) including the valve (68) is constructed of dual lumen tubing (70). The internal diameter of the tubing (70) depends on the required dosage. The tubing (70) is constructed of material compatible with dry nitric oxide gas for the duration of the prescribed therapy. This tubing (70) is glued into the nasal cannula port (72).

The valve (68) is preferably comprised of a flexible flapper (74) that is attached by any mechanism, preferably a spot of adhesive (76), so as to be positioned over the supply tube (70). The flapper (74) must be sufficiently flexible to permit the valve action to be effected by the natural respiration of the patient. When the patient breathes in, the lower pressure in the nasal cannula device (52) causes the flapper (74) of the valve (68) to open and the dry gas is delivered from a reservoir (78) past the flapper (74) and into the patient's respiratory tract. When the patient exhales, positive pressure in the nasal cannula device (52) forces the flapper (74) of the valve (68) closed preventing any delivered gas entering the respiratory tract.

The supplied gas is delivered at a constant rate through the supply tube (70). The rate must be above that required to deliver the necessary concentration to the patient by filling the supply reservoir (78) up to an exhaust port (80) in the supply tube (70) during expiration. When the patient is exhaling the flapper (74) is closed and the supply gas feeds from a supply line (82) through a cross port (84) into the reservoir or storage chamber (78). The length of the reservoir chamber (78) given as dimension (86) determines the volume of gas delivered when

the patient inhales. Inhaling opens the flapper (74) of the valve (68) and causes the reservoir chamber (78) to be emptied.

During exhalation when the flapper (74) is closed and the reservoir chamber (78) is filling, any excess gas exhausts through the exhaust port (80). During inhalation when the reservoir chamber (78) is emptied, the reservoir chamber (78) is displaced with atmospheric air through the exhaust port (80). There will continue to be supply gas from the supply line (82) through the cross port (84) during inhalation and this amount must be figured into the total delivered gas to determine the actual dosage. The tubing lumens (70) include various plugs (88) to direct the flow.

Mask/Valve Adjunct

Referring to Figure 5, there is shown a further embodiment of a nitric oxide valve (54) which is a modification and improvement of a Non-rebreathing valve for gas administration, referred to as a "Modified Fruman Valve," as shown and particularly described in United States of America Patent No. 3,036,584 issued May 29, 1962 to Lee.

More particularly, the within invention specifically redesigns the Modified Fruman Valve for use in inhaled nitric oxide therapy. Specifically, in the preferred embodiment shown in Figure 5, one end of a valve body (90) or valve body chamber is comprised of or includes a mask or mouth-piece (not shown) attached thereto. The connection is preferably standardized to a 22 mm O.D. to facilitate the attachment of the mask or mouth-piece. The other end of the valve body (90) is comprised of or provides an exhaust port (92). The exhaust port (92) entrains ambient air during the latter portion of inspiration and dilutes the nitric oxide coming from an inlet conduit (94).

The resultant nitric oxide concentration in the valve body (90) is determined by the dilutional factors regulated by the valve (54), tidal volume and the nitric oxide concentration in an attached flexed bag (96), being a fixed reservoir

bag. The inlet conduit (94) is preferably spliced for the attachment of the small flexed bag (96). The purpose of the bag (96) is to act as a reservoir for nitric oxide gas. Further, an opening of the inlet conduit (94) is preferably modified to facilitate the attachment or connection of the inlet conduit (94) to a supply hose emanating from a
5 nitric oxide supply chamber. Specifically, the opening of the inlet conduit (94) is preferably comprised of a knurled hose barb connector (98)

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211